However, we also observed significant associations between high expression of WNT activators (e.g., CTNNB1, FZD1, and FZD7) and poor survival of type II non-seminoma GCT patients, suggesting WNT signaling may be a common driver of adverse outcome in GCT patients across age groups. Here, CTNNB1 is linked to seminoma.